Expansion into dermatology through melanocyte-containing autologous cultured epidermis ACE02
First written in FY2019-Q1. 12 of 22 entries say "Advanced", first in FY2019-Q3. Latest entry: 2026-10-30.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Although preparations for adoption at some medical institutions took time, efforts to improve patient access through collaboration with facilities specialising in vitiligo treatment progressed. As a result, the number of core facilities expanded to 42, and orders were secured from new facilities toward the end of the period, laying the foundation for revenue growth.」
For Jasmin, the company advanced collaboration with vitiligo treatment facilities and efforts to improve patient access, expanded the number of core facilities to 42, and secured orders from new facilities. - FY2026-H1AdvancedAnnual report
「Although preparations for adoption at some medical institutions took time, orders have been trending upward toward the second half as the number of core facilities has expanded and patient education activities have progressed. Going forward, we will accelerate the nationwide expansion of core facilities and strengthen information dissemination and awareness activities using the web.」
Although preparations for adoption at medical institutions took time, Jasmin showed a trend toward higher orders in the second half as core facilities expanded and patient education progressed, and advanced to the stage of accelerating nationwide expansion and web-based awareness activities. - FY2025AdvancedAnnual report
「Following reimbursement listing in October 2024, we promoted adoption by core medical institutions and worked to establish the treatment environment. As a result, we received our first order in January and increased the number of cases to 6 during the current fiscal year. Treatment of patients on the waiting list has continued to progress smoothly.」
Following reimbursement listing in October 2024, Jasmin progressed with adoption by core medical institutions and establishment of the treatment environment, received its first order in January 2025, and increased the number of cases to 6 during the current period. - FY2025-H1AdvancedAnnual report
「The melanocyte-containing autologous cultured epidermis Jasmin, approved in March 2023 for vitiligo for which nonsurgical treatment is ineffective or not indicated, was listed for reimbursement effective 1 October 2024 (tissue transport set: ¥4.460 million; cultured epidermis package: ¥154,000 per sheet; covered by the high-cost medical expense benefit system). Going forward, we will work with medical institutions to promote adoption and achieve a smooth launch, while also expanding sales.」
Following marketing approval, Jasmin, which had been developed as ACE02, reached reimbursement listing effective 1 October 2024 and progressed to the stage of promoting adoption and expanding sales through collaboration with medical institutions. - FY2024RestatedAnnual report
「For Jasmin, an autologous cultured epidermis containing melanocytes (pigment cells) for the treatment of vitiligo for which nonsurgical treatment is ineffective or not indicated, marketing approval was obtained on 17 March 2023, and activities are under way toward reimbursement listing.」
Following marketing approval, Jasmin continues reimbursement-listing activities and expansion of the dermatology business. - FY2024-Q3AdvancedAnnual report
「For Jasmin, an autologous cultured epidermis containing melanocytes (pigment cells) for the treatment of vitiligo for which nonsurgical treatment is ineffective or not indicated, marketing approval was obtained on 17 March 2023, and activities are under way toward reimbursement listing.」
The vitiligo treatment product developed as ACE02 obtained marketing approval under the sales name Jasmin, and expansion into dermatology progressed to the reimbursement-listing activities stage following approval. - FY2023-Q2RestatedAnnual report
「On 27 April 2022, we filed an application for marketing approval for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism. Going forward, we aim to grow the dermatology business.」
The company continues to explain the 27 April 2022 application for marketing approval for ACE02 and its policy of growing the dermatology business. - FY2023-Q1RestatedAnnual report
「On 27 April 2022, we filed an application for marketing approval for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism. Going forward, we aim to grow the dermatology business.」
The company continues to explain the 27 April 2022 application for marketing approval for ACE02 and its policy of growing the dermatology business. - FY2022AdvancedAnnual report
「The newly developed autologous cultured epidermis retaining pigment cells, ACE02, completed the clinical trial for stable vitiligo, including non-segmental vitiligo and piebaldism, which had been conducted since July 2018, and an application for marketing approval was filed in April 2022.」
ACE02 progressed, following completion of the clinical trial, to the stage of filing an application for marketing approval dated 27 April 2022. - FY2022-Q1RestatedAnnual report
「We are conducting the clinical trial for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism. Going forward, we will promptly file an application for marketing approval and aim to grow the dermatology business.」
The company continues the ACE02 clinical trial and its policy of expanding into dermatology, with the aim of filing an application for marketing approval in the future. - FY2021-Q2RestatedAnnual report
「We are conducting the clinical trial for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism. We will continue to expand into dermatology through ACE02 and aim to grow the business beyond the plastic surgery and orthopaedic fields in which we have traditionally operated.」
The company continues the ACE02 clinical trial and its policy of expanding into dermatology and growing the business beyond its existing fields. - FY2020RestatedAnnual report
「We conducted the clinical trial for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism.」
The company is continuing the ACE02 clinical trial and aims to expand into dermatology and grow the business beyond its existing plastic surgery and orthopaedic fields. - FY2020-Q3RestatedAnnual report
「We continue to conduct the clinical trial for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism. Through ACE02, we aim to expand into dermatology and grow the business beyond the plastic surgery and orthopaedic fields in which we have traditionally operated.」
The company continues the ACE02 clinical trial and its policy of expanding into dermatology and growing the business. - FY2020-Q2RestatedAnnual report
「We continue to conduct the clinical trial for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism. Through ACE02, we aim to expand into dermatology and grow the business beyond the plastic surgery and orthopaedic fields in which we have traditionally operated.」
The company continues the ACE02 clinical trial and its policy of expanding into dermatology and growing the business beyond the plastic surgery and orthopaedic fields. - FY2019-Q3AdvancedAnnual report
「In July 2018, we submitted a clinical trial notification for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism, and are currently conducting the clinical trial.」
ACE02 progressed from the submission of the clinical trial notification in July 2018 to the current clinical trial stage. - FY2019-Q2RestatedAnnual report
「As another new pipeline for the regenerative medicine products business, we submitted to the Pharmaceuticals and Medical Devices Agency a clinical trial notification for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells). Through ACE02, we aim to expand into the development of regenerative medicine products in dermatology and grow the business beyond the plastic surgery and orthopaedic fields in which we have traditionally operated.」
The company continues to explain the submission of the ACE02 clinical trial notification and its policy of expanding into dermatology and growing the business. - FY2019-Q1First statedAnnual report
「In July 2018, we submitted a clinical trial notification for ACE02, an autologous cultured epidermis retaining melanocytes (pigment cells), for the treatment of stable vitiligo, including non-segmental vitiligo and piebaldism. Conventional transplantation has issues, including limitations on the area of skin tissue that can be harvested, but this product is expected to provide a new treatment that regenerates pigment uniformly over a wide area in a single operation. Through ACE02, we aim to expand into the treatment of dermatological diseases and grow the business beyond the plastic surgery and orthopaedic fields in which we have traditionally operated.」
A new pipeline for expansion into dermatology was launched by submitting a clinical trial notification for ACE02, an autologous cultured epidermis retaining melanocytes, for the treatment of vitiligo.